Evidence map›Paper›PMID 39916591›Full record

ArticlePharmaceutical statistics

Estimation of the Restricted Mean Duration of Response (RMDoR) in Oncology.

Antonios Daletzakis, Kit C B Roes, Marianne A Jonker

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical statistics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Antonios DaletzakisBiometrics Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0002-1151-2250
Kit C B RoesScience Department IQ Health, Section Biostatistics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Marianne A JonkerScience Department IQ Health, Section Biostatistics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0003-0134-8482

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The duration of response (DoR) is defined as the time from the onset of response to treatment up to progression of disease or death due to any reason, whichever occurs earlier. The expected DoR could be a suitable estimand to measure the efficacy of a treatment but is in practice difficult to estimate, since patients' follow-up times are often right-censored. Instead, the restricted mean duration of response (RMDoR) is often used. The RMDoR in a time

Indexed as

Antineoplastic AgentsMedical OncologyNeoplasmsDisease ProgressionHumansTime FactorsTreatment OutcomeAntineoplastic Agentsinterval censoringprogression of the diseaseresponse to treatmentrestricted mean duration of responsesurvival analysis

Identifiers

PMID39916591
PMCPMC11803436

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.